门静脉压力与肝硬度检测预测复发性丙型肝炎持续病毒学应答后肝纤维化逆转
研究纳入2001至2015年间112例达成持续病毒学应答(SVR)的肝移植后复发性丙型肝炎受者,治疗前及SVR后12个月行肝活检并检测肝静脉压力梯度(HVPG)、肝硬度(LSM)和ELF评分。67%患者出现纤维化逆转,HVPG、LSM和ELF显著下降,基线HVPG、LSM及治疗前失代偿为纤维化逆转的独立预测因素;SVR后1年LSM对排除进展期纤维化和临床显著门脉高压有较高诊断准确性。
要点
- 肝移植后复发性丙型肝炎达成SVR者中67%出现纤维化逆转(下降≥1 METAVIR分期)。
- 基线HVPG、LSM及治疗前失代偿是SVR后纤维化逆转的独立预测因素。
- SVR后1年LSM排除进展期纤维化和临床显著门脉高压的AUROC分别为0.902和0.888。
核心结论
- 肝移植后复发性丙型肝炎患者达成SVR可诱导大多数患者纤维化逆转并带来显著临床获益。
- 治疗前HVPG和LSM是纤维化逆转可能性的显著决定因素。
- SVR后1年LSM可准确预测进展期纤维化和门脉高压的存在,因而可用于确定监测策略。
研究设计与样本
- 研究评估了2001至2015年间达成SVR的112例丙型肝炎病毒感染的肝移植受者。
- 治疗前及SVR后12个月行肝活检,并在相同时间点检测HVPG、LSM和ELF评分。
主要发现
- 67%的队列出现纤维化逆转:肝硬化受者为43%,其余分期为72%-85%(P=0.002)。
- SVR后HVPG、LSM和ELF显著下降。
- 达成纤维化逆转的患者肝功能显著改善且生存显著更优。
- 基线HVPG和LSM以及治疗前失代偿是纤维化逆转的独立预测因素。
- SVR后1年LSM排除进展期纤维化和临床显著门脉高压的AUROC分别为0.902和0.888。
临床怎么用
- 作者认为SVR后1年LSM可准确预测进展期纤维化和门脉高压的存在,因而可用于确定监测策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Sustained virological response (SVR) improves survival in post-liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined. In addition, the performance of noninvasive methods to evaluate the presence of fibrosis and portal hypertension (PH) post-SVR has been scarcely evaluated. We aimed to investigate the degree of fibrosis regression (decrease ≥1 METAVIR stage) after-SVR and its associated factors in recurrent hepatitis C, as well as the diagnostic capacity of noninvasive methods in the assessment of liver fibrosis and PH after viral clearance. We evaluated 112 hepatitis C virus-infected LT recipients who achieved SVR between 2001 and 2015. A liver biopsy was performed before treatment and 12 months post-SVR. Hepatic venous pressure gradient (HVPG), liver stiffness measurement (LSM), and Enhanced Liver Fibrosis (ELF) score were also determined at the same time points. Sixty-seven percent of the cohort presented fibrosis regression: 43% in recipients with cirrhosis and 72%-85% in the remaining stages (P = 0.002). HVPG, LSM, and ELF significantly decreased post-SVR. Liver function significantly improved, and survival was significantly better in patients achieving fibrosis regression. Baseline HVPG and LSM as well as decompensations before therapy were independent predictors of fibrosis regression. One year post-SVR, LSM had a high diagnostic accuracy to discard the presence of advanced fibrosis (AF) and clinically significant PH (AUROC, 0.902 and 0.888). CONCLUSION: In conclusion, SVR post-LT induces fibrosis regression in most patients, leading to significant clinical benefits. Pretreatment HVPG and LSM are significant determinants of the likelihood of fibrosis regression. Finally, LSM accurately predicts the presence of AF and PH 1 year after SVR and thus can be used to determine monitoring strategies. (Hepatology 2018;67:1683-1694).
引用
- Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology. 2018. PMID: 28960366. doi:10.1002/hep.29557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。